RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Calliditas Therapeutics - Stock

Calliditas Therapeutics Stocks 2024

Calliditas Therapeutics Stocks

53.67 M

Ticker

CALTX.ST

ISIN

SE0010441584

WKN

A2JP36

In 2024, Calliditas Therapeutics had 53.67 M outstanding stocks, a 0% change from the 53.67 M stocks in the previous year.

The Calliditas Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined SEK)
2029e53.67
2028e53.67
2027e53.67
2026e53.67
2025e53.67
2024e53.67
202353.67
202253.02
202150.83
202044.87
201936.94
201825.95
201733.23
201633.23
201533.23

Calliditas Therapeutics shares outstanding

The number of shares was Calliditas Therapeutics in 2023 — This indicates how many shares 53.672 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Calliditas Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Calliditas Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Calliditas Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Calliditas Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Calliditas Therapeutics Aktienanalyse

What does Calliditas Therapeutics do?

Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. The company's goal is to develop innovative therapies for rare diseases and treat patients worldwide. The company is divided into two main business areas: clinical development and commercial products. The clinical development area focuses on identifying, developing, and marketing drugs for the treatment of kidney and liver diseases, as well as autoimmune diseases. The commercial products area distributes the developed medications. Calliditas' business model is based on the discovery and exploration of therapies for rare diseases. The company divides its pipeline into different product categories such as kidney and liver diseases, as well as autoimmune diseases. It is expected that this pipeline will make further progress over time and bring several products to market. Currently, Calliditas is in Phase 3 of clinical trials for Nefecon, a medication for the treatment of IgA nephropathy. IgA nephropathy is a rare kidney disease in which immunoglobulin A deposits in the kidneys can cause inflammation and damage. Nefecon is being developed to reduce the production of IgA and thereby reduce inflammation in the kidneys. Calliditas is also in Phase 2 of clinical trials for Atimmune, a medication for the treatment of autoimmune diseases. Atimmune aims to modulate the immune system to treat autoimmune diseases naturally. In addition, Calliditas is currently working on another medication for the treatment of liver diseases called FT-4202. FT-4202 is intended to increase the production of hemoglobin and thereby alleviate the symptoms of sickle cell anemia. Calliditas has an experienced team of researchers, clinicians, and salespeople dedicated to the development of medications for rare diseases. The company collaborates closely with experts in the field of kidney and liver diseases, as well as autoimmune diseases, to improve the development and marketing of its products. The company has also formed partnerships with other companies and industry stakeholders to support its research and development efforts. For example, Calliditas has entered into an agreement with Everest Medicines Ltd., a Chinese biotech company specializing in rare diseases, to market and distribute Nefecon in China. Overall, Calliditas has a promising pipeline of medications for the treatment of rare diseases. The company is well positioned to succeed in the coming years and improve the lives of patients around the world. Calliditas Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Calliditas Therapeutics's Shares Outstanding

Calliditas Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Calliditas Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Calliditas Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Calliditas Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Calliditas Therapeutics stock

How many stocks are there of Calliditas Therapeutics?

The current number of stocks of Calliditas Therapeutics is 53.67 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Calliditas Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Calliditas Therapeutics evolved in recent years?

The number of shares of Calliditas Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Calliditas Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Calliditas Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Calliditas Therapeutics pay?

Over the past 12 months, Calliditas Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calliditas Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of Calliditas Therapeutics?

The current dividend yield of Calliditas Therapeutics is .

When does Calliditas Therapeutics pay dividends?

Calliditas Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calliditas Therapeutics?

Calliditas Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Calliditas Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calliditas Therapeutics located?

Calliditas Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calliditas Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calliditas Therapeutics from 7/8/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Calliditas Therapeutics pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of Calliditas Therapeutics in the year 2023?

In the year 2023, Calliditas Therapeutics distributed 0 SEK as dividends.

In which currency does Calliditas Therapeutics pay out the dividend?

The dividends of Calliditas Therapeutics are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Calliditas Therapeutics

Our stock analysis for Calliditas Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calliditas Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.